We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





BD Presents Latest Automated Solutions to Combat Antimicrobial Resistance at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) presented its latest automation solutions for clinical laboratories, which may play a critical role in the fight against infectious diseases and antimicrobial resistance at ECCMID 2022. More...

BD showcased its Kiestra lab automation solutions that provide total lab automation for the clinical microbiology lab through modularity, scalability and open architecture. These solutions are designed to increase efficiency, streamline processes, and deliver high quality and consistent results with improved turnaround time. BD Kiestra lab automation offerings include complementary and modular microbiology workflow automation solutions, ranging from standalone units to fully automated track-based automation systems for mid- and high-volume labs.

On display was the BD Kiestra IdentifA solution, which is available as part of a track-based BD Kiestra laboratory automation solution, and supports specimen preparation workflows for routine and challenging isolate types in combination with identification on the BD Bruker MALDI Biotyper. The BD Kiestra IdentifA solution helps bring accuracy and efficiency to preparing samples for microbial identification. By automating the sample processing steps required to identify a microorganism, this solution helps reduce potential for user error while providing clinicians with bacterial identification for a patient suspected of having an infection.

BD also demonstrated its BACTEC FX blood culturing instruments used with patented resin-containing media have shown higher rates of organism recovery, allowing for proper diagnosis and treatment of bloodstream infections. The BD BACTEC FX builds on the proven superior fluorescence detection technology, exceptional media performance and instrument reliability of the BD BACTEC 9000 blood culture systems. Also on display at the event was the BD MAX System, a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.

Related Links:
Becton, Dickinson and Company 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.